Browse Health
Internist, Critical Care Specialist
25 years of experience
Accepting new patients

Education ?

Medical School Score Rankings
The University of Texas Southwestern (1985)
  • Currently 4 of 4 apples
Top 25%

Awards & Distinctions ?

Awards  
Castle Connolly Top Doctors: Texas™ (2009)
Associations
American Board of Internal Medicine

Affiliations ?

Dr. Martinez is affiliated with 11 hospitals.

Hospital Affilations

Score

Rankings

  • Texas Health Harris Methodist Hospital Azle
    108 Denver Trl, Azle, TX 76020
    • Currently 3 of 4 crosses
    Top 50%
  • Texas Health Harris Methodist Hospital Southwest Fort Worth
  • Texas Health Presbyterian Hospital Of Dallas
  • Harris Continued Care Hospital
    1301 Pennsylvania Ave, Fort Worth, TX 76104
  • Harris Methodist - Springwood
    1608 Hospital Pkwy, Bedford, TX 76022
  • Harris Methodist H E B
  • Baylor All Saints
  • Texas Health Fort Worth
  • Baylor All Saints Medical Centers
  • Texas Health Harris Methodist Hospital Fort Worth
  • Lifecare
  • Publications & Research

    Dr. Martinez has contributed to 2 publications.
    Title Intralesional Administration of Epidermal Growth Factor-based Formulation (heberprot-p) in Chronic Diabetic Foot Ulcer: Treatment Up to Complete Wound Closure.
    Date July 2009
    Journal International Wound Journal
    Excerpt

    Previous studies have shown that an epidermal growth factor-based formulation (Heberprot-P) can enhance granulation of high-grade diabetic foot ulcers (DFU). The aim of this study was to explore the clinical effects of this administration up to complete wound closure. A pilot study in 20 diabetic patients with full-thickness lower extremity ulcers of more than 4 weeks of evolution was performed. Mean ulcer size was 16.3 +/- 21.3 cm(2). Intralesional injections of 75 microg of Heberprot-P three times per week were given up to complete wound healing. Full granulation response was achieved in all 20 patients in 23.6 +/- 3.8 days. Complete wound closure was obtained in 17 (85%) cases in 44.3 +/- 8.9 days. Amputation was not necessary in any case and only one relapse was notified. The most frequent adverse events were tremors, chills, pain and odour at site of administration and local infection. The therapeutic scheme of intralesional Heberprot-P administration up to complete closure can be safe and suitable to improve the therapeutic goal in terms of healing of chronic DFU.

    Title Developing Country Vaccine Manufacturers Network (dcvmn), 26-27 April 2001, Bandung, Indonesia.
    Date January 2002
    Journal Vaccine

    Similar doctors nearby

    Dr. Ramu Rangineni

    Internal Medicine
    13 years experience
    Fort Worth, TX

    Dr. Wilder Diaz Calderon

    Internal Medicine
    12 years experience
    Fort Worth, TX

    Dr. Mauricio Ruiz-Baron

    Internal Medicine
    10 years experience
    Fort Worth, TX

    Dr. Adib Asrabadi

    Internal Medicine
    4 years experience
    Fort Worth, TX

    Dr. David Ruiz-Bello

    Internal Medicine
    10 years experience
    Fort Worth, TX

    Dr. Durga Nelapolu

    Internal Medicine
    12 years experience
    Fort Worth, TX
    Search All Similar Doctors